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Introduction: Human placental protein 13 (PP13) is a galectin predominantly expressed by 
the placenta. Low serum concentrations of PP13 in early pregnancy indicate a higher risk of 
developing preeclampsia.
Methods: The pharmacokinetic disposition and bioavailability of PP13 were determined by 
single intravenous and subcutaneous administration to 12 healthy New Zealand White rabbits. 
The serum pharmacokinetic values were determined by enzyme-linked immunosorbent assay, 
and are best described by a two-compartment model.
Results: Both volume of distribution and the area under the curve were dose dependent for the 
intravenous group (p,0.01). PP13 elimination half-life was also found to be different between 
the groups (p,0.01). The bioavailability of PP13 following subcutaneous administration was 
found to be 57%.
Conclusion: This study shows that the concentration of total PP13 released into the maternal 
circulation during pregnancy might be much higher than previously estimated.
Keywords: PP13, ELISA, PK, eNOS, prostaglandin, preeclampsia
Introduction
Human placental protein 13 (PP13) is a member of placentally expressed proteins and 
of β-galactoside-binding proteins or galectins.1,2 PP13 was first isolated in 1983 by 
Bohn from human placenta3 and is predominantly expressed in this organ;4 however, 
Than et al have reported its presence in rare tumors of fetal spleen and liver tissues as 
well.1 Several studies in humans have shown that low PP13 levels in maternal serum 
early in pregnancy are associated with the subsequent development of preeclampsia,5,6 
an obstetrical complication affecting around 2%–5% of all pregnancies and one of 
the leading causes of maternal and perinatal morbidity and mortality.7,8 Preeclampsia 
is a disorder characterized by a constellation of signs and symptoms, eminently new 
onset of hypertension and proteinuria developed from the midst of pregnancy in previ-
ously normotensive women with no such symptoms.7,8 Later in life, the disorder can 
increase the frequency of developing cardiovascular diseases in women with a history 
of preeclampsia.9,10 Earlier meta-analyses of PP13 across various studies in humans have 
described a significant decrease in circulating concentrations in early pregnancy in those 
women developing preeclampsia later in pregnancy.1 This decrease might be directly 
related to the severity of the disorder. Other parameters like ethnic origin, obesity, blood 
groups, and genetic polymorphism of the protein’s primary sequence play a major role 
in the severity of preeclampsia and especially among women of African origin.6,11–14
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PP13 is secreted from the placental syncytiotrophoblast, 
and as galectin 13, it shows structural homologies to other 
members of the galectin family.15 It has high affinity for sugar 
residues and is implied to be involved in conferring immu-
notolerance of the mother at the site of trophoblast invasion 
during uterine artery remodeling in early pregnancy in order 
to enable deep placentation.16–19
Studies performed in rats have shown that PP13 decreases 
blood pressure,20 and it has been shown to induce vasodilation 
of resistance arteries through endothelial signaling involving 
the pathways of endothelial nitric oxide synthase (eNOS) 
and prostaglandin.21 In rats, PP13 administration results in 
larger pups and heavier placentas due to a possible increase 
in blood flow and oxygen supply to the uterine vasculature 
in pregnancy. It has been suggested that PP13 replenishing 
in pregnancies with low maternal serum level may assist in 
preventing preeclampsia.5,12,22 Thus, it is important to under-
stand the availability of PP13 administrated externally. The 
aim of the current study was to determine the kinetic disposi-
tion and bioavailability of PP13 in serum after intravenous 
(IV) and subcutaneous (SC) administration of the protein in 
healthy rabbits.
Materials and methods
animals and ethics approval
Twelve female nonpregnant New Zealand White (NZW) 
rabbits were purchased from Envigo (Huntington, UK) and 
housed at the laboratory animal care facility at the University 
of Iceland (Reykjavik, Iceland).
The NZW rabbits, each weighing on average 3.9±0.3 kg, 
were caged in groups of three with access to food and water 
ad libitum and maintained on a 12/12 h light/dark cycle.
The study was approved by the Icelandic Animal Ethic 
Committee (study number: 2015-09-02) and carried out 
according to the US National Institutes of Health Guide for 
the Care and Use of Laboratory Animals. All efforts were 
undertaken according to the “3R principles” (www.nc3rs.
org.uk) to reduce the number of animals used in the study 
and optimize experimental protocols for obtaining maximum 
data from each tested animal.
Placental protein 13
Recombinant PP13 without the histidine tag was prepared 
by expressing the recombinant wild-type PP13 construct in 
Escherichia coli, harvesting, and purification as was already 
described,21 and its DNA sequence was verified by Sanger 
sequencing (https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC431765/). The molecular weight and the purity of the pro-
tein were verified by sodium dodecyl sulphate polyacrylamide 
gel electrophoresis, high performance liquid chromatography, 
and immunoblots with PP13-specific monoclonal antibodies. 
The concentration was determined using a PP13 enzyme-linked 
immunosorbent assay (ELISA) kit as previously described.23
experimental procedure
The animals were divided into four experimental groups 
(n=6/group). Each animal was assigned to one group, allowed 
to rest for a week, and then allocated to a different experi-
mental group. Three groups received IV injection (1.3, 2.6, or 
12.8 ng/kg) of PP13 that was administered into the right marginal 
ear vein. The fourth group received SC injection (12.8 ng/kg), 
administered under the skin, at the neck area on the back.
PP13 was diluted in 0.9% saline solution at 5, 10, and 
50 ng/mL, corresponding to concentrations of 1.3, 2.6, and 
12.8 ng/kg, respectively, and was administered as a single 
IV injection or by SC route (only 12.8 ng/kg).
A blood control sample of ~1 mL was collected from the 
marginal vein of the left ear (opposite to the administration 
side) of each animal and stored into serum vacutainer tubes. 
The blood was collected prior to protein administration (T
0
) 
and also at a time series of 10, 30, 60, and 90 min and 2, 4, 6, 
and 24 h after PP13 administration.
Blood samples were centrifuged within 2 h after col-
lection, and the separated serum was kept frozen at −80°C 
until further analysis. The storage at −80°C does not have 
any impact on PP13 protein stability.24
analytical assay
PP13 in the serum samples was determined by a commercially 
available ELISA kit from Cusabio (Wuhan, China; category 
number: CSB-E12733h). All the samples were analyzed in 
duplicates. The working range of the assay is from 2.5 to 
1,000 pg/mL. Calibration curves had a regression coefficient 
at R2.0.99. Intraassay precision and interassay precision 
had a coefficient of variance of 10% and 11%, respectively. 
Interassay precision was determined by measuring standard 
samples on three separate days. The calibration curves were 
fitted with a four-parameter logistic equation.
Pharmacokinetics and statistical analysis
PP13 serum concentrations of each animal were analyzed over 
time using GraphPad Prism (GraphPad Software, San Diego, 
CA, USA). To describe the pharmacokinetics of PP13 after 
both IV and SC administration, a two-compartment model 
with linear elimination was used. Data were collected and 
calculated in Microsoft Excel, using standard pharmacoki-
netic equations and simulations. All statistics were performed 
using GraphPad InStat on Prism (GraphPad Software).
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The absorption half-life (t
1/2
 
abs
), elimination half-life (t
1/2
), 
elimination constant (β), distribution rate constant (α), and 
total body clearance (Cl
tot
) were calculated. Areas under the 
serum concentration–time curves for both IV (area under 
the curve [AUC]
IV0→∞) and SC (AUCSC0→∞) injections were 
calculated by the method of trapezoids and presented as pg 
PP13 per h/mL (pg⋅h/mL). Peak serum PP13 concentration 
(C
max
) and time to reach C
max
 (t
max
) were determined directly 
from the individual serum concentration–time curves for 
the SC administration. Also, the bioavailability of PP13 
(F%=AUC
SC
/AUC
IV
×100) was calculated. All results are 
presented as mean ± SD. Harmonic means were calculated for 
t
1/2
 and AUC and presented as mean ± standard error (SE).
Mann–Whitney U test was used to evaluate the statistical 
significance of the differences in t
1/2
. The AUCs were com-
pared using the independent samples t-test. p,0.05 was 
considered statistically significant for all tests. Student’s t-test 
was used for data comparison between groups. All values are 
presented as mean ± SD, but t
1/2
 and AUC
0→24h are presented 
as harmonic mean ± SE.
Results
iV administration
Serum concentration–time profiles of PP13, following single-
dose IV administration of 1.3, 2.6, and 12.8 ng/kg, are shown 
in Figure 1. The two-compartment model was found to fit 
best for the majority of animals and used to calculate the 
pharmacokinetic parameters. The calculated values for AUC 
were 315±47, 495±28, and 1,360±82 pg⋅h/mL for 1.3, 2.6, 
and 12.8 ng/kg, respectively. When corrected for the dose 
given, AUC was equivalent to 246, 193, and 106 pg⋅h/mL, 
showing that there is a drastic significant reduction in AUC 
with increased dose ( p=0.004). Likewise, when volume 
of distribution (Vd) was compared, there was a significant 
difference in the value between the lowest and the highest 
dose (p,0.001). These findings suggest that PP13 binding 
reached saturation, and thus, it appears that the protein might 
follow nonlinear pharmacokinetics.
The half-life following IV injection was calculated to 
be 5.16±0.97, 4.42±0.77, and 4.60±0.09 h for these three 
doses, respectively. The clearance for these three doses 
was found to be 14.0±1.9, 20.3±3.5, and 33.5±2.6 mL/kg/h, 
respectively.
sc administration
Mean serum concentration–time profiles of PP13 following 
SC administration of a single dose (12.8 ng/kg), in compari-
son with IV administration, are presented in Figure 2. The 
corresponding pharmacokinetic parameters were obtained 
by the two-compartmental analysis. Following SC admin-
istration of a single dose at 12.8 ng/kg, the t
1/2
, t
1/2
 
abs
, C
max
, 
AUC, and Cl were 11.4±1.0 h, 4.5±0.4 h, 130±11 pg/mL, 
805±62 pg⋅h/mL, and 60.4±12.5 mL/kg/h, respectively. 
Based on the equivalent IV dose, the bioavailability (F) was 
calculated to be 57.1%±3.2%.
When the study was performed, all rabbits were clini-
cally healthy and no side effects were observed after the 
administration of PP13 at any concentration, either after IV 
(1.3, 2.6, and 12.8 ng/kg) or after SC (12.8 ng/kg) injections. 
SC administration was less invasive and easier to manage.
250
200
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nt
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Dose–response curves after
IV administration
150
100
50
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Figure 1 serum concentration–time curves after single iV administration.
Notes: group 1: 5 ng/ml (1.3 ng/kg), n=6; group 2: 10 ng/ml (2.6 ng/kg), n=6; and 
group 3: 50 ng/ml (12.8 ng/kg), n=6. Data are reported as mean ± sD.
Abbreviation: iV, intravenous.
Figure 2 serum concentration–time curves after single iV and sc administration of 
50 ng/ml (12.8 ng/kg), n=6.
Note: Data are reported as mean ± sD.
Abbreviations: iV, intravenous; sc, subcutaneous.
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comparison of parameters between the 
routes of administration
The half-life (t
1/2
) was significantly different between the 
IV and SC groups receiving the equivalent dose (p=0.002). 
AUC and Cl
tot
 were also found to be significantly different 
(p,0.001). After the SC administration, PP13 reached the 
C
max
 at 90 min, and the bioavailability was calculated to 
be about 57%, compared with the same dose administered 
intravenously. The protein was almost completely eliminated 
from the blood during the next 24 h in all groups.
The comparison between the different doses (1.3 and 12.8 
ng/kg) for IV administration revealed a significant difference 
between AUC/dose (p=0.004) and Vd (p,0.001).
The pharmacokinetic parameters of PP13 for both IV 
and SC administration routes are presented in Table 1.
Discussion
Rabbits are among the most commonly used animals in 
preclinical drug development, and it is of utmost importance 
to understand the differences and similarities in the pharma-
cokinetic behavior of drug molecules for proper interpretation 
and integration in the development process for therapies. 
Therefore, the current study was designed to investigate the 
pharmacokinetic profile of PP13 in rabbits via two admin-
istration routes, and to our knowledge, this study is the first 
report describing the pharmacokinetics of PP13.
In our previous study conducted in rats, we observed 
that PP13 was a highly active vasodilator, acting via the 
vascular endothelium through both eNOS and prostaglandin 
signaling pathways.21 We have also observed that intraperi-
toneal delivery of PP13 from osmotic pumps in pregnant rats 
reduced blood pressure.20 The effect of PP13 in both rodents 
and lagomorphs is considered pharmacological, since both 
species lack the LGALS13 gene encoding for the protein, 
which is specific to primates.4,16
The absorption kinetics of proteins following SC adminis-
tration and the distribution of proteins to various tissues are a 
complex interaction of multiple processes, including absorp-
tion by lymphatic capillaries, interstitial transport, specific 
and nonspecific binding, and presystemic degradation.25,26 
The structure of the skin as well as the SC space might have 
an impact on drug absorption as well.26
In this study, we observed a relatively short half-life of the 
protein in all groups. These findings might indicate a rapid elimi-
nation of PP13. The rapid elimination could be accounted for 
by antigen binding to red blood cells14 and vascular endothelial 
blood vessels,21 or by tight binding of PP13 (a galectin) to puta-
tive tissue receptors (eg, sugar residues of various proteins).27
The dose-corrected pharmacokinetic difference between 
1.3 and 12.8 ng/kg dose groups (IV), for both AUC and Vd, 
presented in Table 1, was unusual and may be explained 
by the overall effect that the protein might have on blood 
pressure,20 endothelium, and selected arteries and veins.21
Table 1 Pharmacokinetic parameters for both administration routes based on individual data
Parameters Group 1 
(1.3 ng/kg IV)
Group 2 
(2.6 ng/kg IV)
Group 3 
(12.8 ng/kg IV)
Group 4 
(12.8 ng/kg SC)
p-value (Group 3 
vs Group 4)
p-value 
(IV groups)
t1/2 (half-life) (h)
a 5.16±0.97 4.42±0.77 4.60±0.09 11.40±1.03 0.002** 0.29
t1/2 abs (h) n/a n/a n/a 4.50 n/a n/a
ke (h
−1) 0.15±0.07 0.16±0.03 0.15±0.01 0.06±0.02 n/a n/a
kabs (h
−1) n/a n/a n/a 1.78±0.34 n/a n/a
α (h−1)b 0.36±0.14 0.50±0.13 0.60±0.23 0.24±0.09 n/a n/a
β (h−1)b 0.09±0.03 0.13±0.04 0.04±0.03 0.14±0.04 n/a n/a
MrT (h) 1.84±0.19 1.23±0.17 0.62±0.18 n/a n/a n/a
Vdss (ml/kg) 25.8±0.0 25.7±0.0 14.3±0.7 n/a n/a n/a
aUc0→24h (pg⋅h/ml)
a 315±47 495±28 1,360±82 805±62 0.001**,b n/a
Cltot (ml/kg/h) 14.0±1.9 20.3±3.5 33.5±2.6 60.4±12.5 0.001** 0.001**
Cmax (pg/ml) 58.4±10.9 78.9±9.6 217.0±19.3 130.0±11.4 n/a n/a
tmax (min) n/a n/a n/a 90 n/a n/a
Vd (l) 110±13 132±20 228±33 1,126±498 n/a 0.0001**
VdaUc (l) 3.05±0.74 3.89±0.93 6.40±1.94 n/a n/a n/a
aUc/dose (h/ml) 0.07±0.02 0.05±0.01 0.03±0.004 0.02±0.003 n/a 0.004**
F% n/a n/a n/a 57.1±3.2 n/a
Notes: each group contained 6 rabbits. aharmonic mean. bp-value was calculated between two groups where the same concentration of the drug was given. **p0.001.
Abbreviations: aUc, area under the concentration–time curve; aUc/dose, aUc corrected for dose; Cltot, total body clearance; Cmax, maximal plasma concentration; F%, 
bioavailability; iV, intravenous; kabs, absorption rate constant; ke, elimination constant; MrT, mean resistance time; n/a, not applicable; sc, subcutaneous; t1/2 abs, absorption 
half-life; t1/2, half-life; tmax, time to maximum concentration; Vd, volume of distribution; VdaUc, Vd corrected for aUc; Vdss, volume of distribution at steady state; α, distribution 
rate constant; β, elimination rate constant.
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The specific binding site for PP13 has not yet been 
defined, although, similar to most galectins, PP13 might 
bind to sugar residues, such as N-acetyl-lactosamine and 
lactose.27 Studies from affinity chromatography and mass 
spectroscopy identified high-affinity binding of PP13 to 
annexin II and β-/γ-actin.1 Annexin II is expressed on both 
activated and resting endothelial cells,28,29 and PP13 mainly 
works on the endothelial layer of arteries.21 In addition, the 
binding can be to sugar residues of the B and AB antigens 
of the ABO blood groups (oligosaccharides conjugated to 
cell-surface glycolipids and glycoproteins), as was shown 
by Than et al.14 Such interactions are potentially important 
regulators for the availability of free PP13 in the blood circu-
lation and have been found to influence the prediction of the 
risk to develop preeclampsia30 and should also be considered 
for PP13 bioavailability in rabbits, which also carry different 
blood groups.31
In a study by Huppertz et al,5 in which the serum levels 
of PP13 were measured throughout pregnancy, the authors 
reported a 1.4- to 2-fold increase in the blood levels of PP13 
in normal pregnancies between the first and third trimesters. 
The starting concentrations were around 200 pg/mL in 
early pregnancy (gestational weeks 5–8) reaching about 
400 pg/mL in late pregnancy (gestational weeks 36–40).5 
In normal pregnancy, maternal blood PP13 level almost 
completely disappears within few weeks after delivery and 
placental removal. However, women who later developed 
preeclampsia had serum levels under 50 pg/mL in the first 
trimester, followed by a 7- to 15-fold increase of PP13 by 
week 36.5 PP13 serum levels in these women vanished very 
slowly after delivery and could be determined for 5–6 weeks 
postpartum and occasionally longer.5 A recent study by 
Madar-Sharipo et al36 has shown that combining the presence 
of the A/A genotype in the −98 site of the PP13 promoter with 
obesity, African (black) origin, and history of preeclampsia 
significantly increases the accuracy of predicting the risk 
of preeclampsia.28 The determination of low serum levels 
of PP13 in early pregnancy contributes to the prediction of 
preeclampsia as well. Therefore, it is tempting to suggest 
the possible utility of PP13 as a biomarker for predicting 
the disorder.4,16,17
Immunostaining for PP13 in human placentas showed 
that it is found in the cytoplasm and brush border membrane 
of the syncytiotrophoblast and its microparticles (STBMs) 
that are subsequently shed into the maternal circulation along 
with their PP13 content.32
Based on this study and previous findings, we hypoth-
esize that an elevated amount of PP13 that is released from 
the placenta into the maternal circulation via STBMs or as 
free molecules circulates in the maternal blood where it may 
bind to blood vessels, red blood cells, and potentially to other 
maternal organs. Hence, the apparent amount of free PP13 
that is determined in the blood is just a fraction of the total 
PP13 released from the placenta.
We propose that the free PP13 determined in the rabbit 
blood samples may vary due to factors such as 1) high-affinity 
binding to the AB and B antigens of the ABO blood groups;13 
2) specific binding to endothelial binding sites related to 
the eNOS and prostaglandin
2
 pathways;21 and 3) blood 
vessel vasodilation and hypotension induced by PP13,35 
which may also influence 4) the peripheral blood return and 
potentially also the cardiac output. The latter is extremely 
important when looking at uterine arteries where it has been 
shown that the Doppler pulsatility index (arterial stiffness and 
resistance) is higher in patients who subsequently developed 
preeclampsia.33 It was also shown that combining low PP13 
with high uterine arteries Doppler pulsatility index can accu-
rately predict the risk to develop preeclampsia.22,33,34
If PP13 release from the placental STBMs is considered to 
be constant in early pregnancy, using a theoretical concentra-
tion at steady state (C
ss
) of 300 pg/mL (corresponding to the 
average serum levels in normal pregnancies), and data used 
in this study for allometric scaling between species, then the 
PP13 dose that is released into the circulation is 1.07 pg/h in 
unaffected pregnancies. When correcting the serum concen-
tration of women who are at risk for developing preeclampsia, 
the loading IV dose would be around 50 pg/kg of PP13 and 
90 pg/kg if given through SC route. To maintain the correct 
serum concentration of PP13 throughout pregnancy, based on 
our data, the dose required would be 10 pg/kg if given daily 
through IV route or 20 pg/kg if given through SC route.
This study has limitations since it was conducted in 
nonpregnant rabbits, and in addition, as mentioned previ-
ously, the LGALS13 gene is expressed in primates but not in 
rabbits. Therefore, the overall antigen binding of PP13 might 
differ between species. Galectins can undergo pinocytosis into 
exosomes that are being released form the placenta. However, 
this transfer has not yet been elucidated for PP13 outside the 
placenta. This could be another limitation of our study.
When it comes to the clinical setting of the protein, as 
described previously, IV administration is unlikely to be 
used; however, understanding the pharmacokinetic behavior 
of the drug after IV bolus administration is important. 
Dose-dependent parameters differ between IV doses. It is 
suggested that the dose-dependent pharmacokinetics might 
be explained by the effect PP13 has on the vascular system, 
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as reported in our previous studies.20,21,35 Thus, when it comes 
to administration of PP13 to pregnant women, the duration 
of the drug administration and total volume remain to be 
tested in greater detail.
Finally, the protein absorption by the lymphatic capil-
laries was not evaluated here and might be considered as 
another limiting factor.
Conclusion
Based on our findings, we hypothesize that the circulating 
blood levels of PP13 determined by various methods represent 
only a fraction of what is secreted by the placenta. The rest 
remains bound to red blood cells, the endothelial layer, and 
other maternal organs. The study provides important informa-
tion regarding the basic pharmacokinetic parameters, where 
some factors were found to be affected by increasing dosage. 
To estimate the overall systemic distribution of PP13, addi-
tional studies are required. In addition, since rabbits are not 
identical to humans, further studies in humans are needed.
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